Controversies in Ocular Myasthenia Gravis

Area of Science:

• Neurology
• Ophthalmology

Background:

• Ocular myasthenia gravis (OMG) is a rare subtype of myasthenia gravis affecting only eye muscles.
• Incidence is increasing, particularly in the elderly, and prevalence is growing in Western countries.
• OMG presents with painless ptosis and ophthalmoparesis, sometimes mimicking other cranial nerve disorders.

Purpose of the Study:

• To review the incidence, diagnosis, and management of ocular myasthenia gravis.
• To highlight diagnostic challenges and current treatment strategies.
• To discuss the exclusion of OMG from recent generalized MG treatment advancements.

Main Methods:

• Literature review of ocular myasthenia gravis.
• Analysis of diagnostic criteria and challenges.
• Summary of current therapeutic approaches and controversies.

Main Results:

• OMG incidence varies by ethnicity and age, with a noted increase in older populations.
• Diagnostic confirmation can be difficult, especially in antibody-negative cases.
• Steroids are commonly used for symptom relief, with immunosuppressants for refractory cases; thymectomy's role is debated.

Conclusions:

• Early recognition and management of OMG are essential to alleviate symptoms and prevent generalization.
• Current treatments for OMG are limited, and it is often excluded from novel therapies developed for generalized MG.
• Further research is needed to address the specific needs and treatment gaps for OMG patients.